Wydanie specjalne czerwiec 2017
str. 17 - 20

Ocena wyników leczenia chorych na neowaskularną postać zwyrodnienia plamki związanego z wiekiem doszklistkowymi iniekcjami afliberceptu w ramach programu lekowego Narodowego Funduszu Zdrowia

Outcomes in Patients with Neovascular Age-related Macular Degeneration Treated with Aflibercept Injections as a Part of National Health Fund Drug Prescription Program

Piotr Wnorowski, Tomasz Chudoba, Ewa Kardasiewicz, Joanna Sempińska-Szewczyk

Oddział Okulistyki Centralnego Szpitala Klinicznego MSWiA w Warszawie
Kierownik: dr n. med. Joanna Sempińska-Szewczyk


Summary: Purpose: To evaluate outcomes of aflibercept intravitreal injections in treatment- naïve patients with neovascular age-related macular degeneration treated as a part of the National Health Fund Drug Prescription Program.
Material and Methods: A retrospective analysis of treatment history of 17 eyes of 16 treatment – naïve patients with neovascular age-related macular degeneration treated with 3 monthly injections of afliberept, followed by 1 injection every 2 months. All patients received at least 5 aflibercept injections. The observation period ranged from 9 to 13 months. Best corrected visual acuity and central retinal thickness were reviewed before the first and 2 months after the last injection.
Results: The number of aflibercept injections in analyzed group ranged from 5 to 7 (mean 5.8). Visual acuity improved in 94% of patients by 1 line or more on Snellen charts. Mean increase in visual acuity was 1.8 line. In all cases retinal morphology on optical coherence tomography scans improved and central retinal thickness decreased by 91.76 µm on average. In 3 patients residual subretinal fluid was observed 2 months after the last injection. No serious adverse events of the treatment were reported.
Conclusions: Aflibercept administered to patients with neovascular age-related macular degeneration during the first year of therapy according to Drug Prescription Program schedule proves to be very efficient and safe treatment option.

Słowa kluczowe: aflibercept, ranibizumab, inhibitory śródbłonkowego czynnika wzrostu (preparaty anty-VEGF), zwyrodnienie plamki związane z wiekiem (AMD), iniekcje doszklistkowe.

Keywords: aflibercept, ranibizumab, anti-vascular endothelial growth factor inhibitors (anti-VEGF), age-related macular degeneration (AMD), intravitreal injection.


powrót

REDAKCJA NIE UDZIELA PORAD MEDYCZNYCH I NIE POŚREDNICZY W KONSULTACJACH PACJENTÓW Z LEKARZAMI